Table 1

Current diagnostic guidelines for TA-TMA

CategoryBlood and Marrow Transplant Clinical Trials Network18 International Working Group of the European Group for Blood and Marrow Transplantation58 Probable TMA as defined by validation study by Cho et al53 
Schistocytes ≥ 2 per high-power field in peripheral blood > 4% in peripheral blood ≥ 2 per high-power field in peripheral blood 
LDH Increased above institutional baseline Sudden and persistent increase Increased 
Renal function Doubling of serum creatinine or 50% decrease in creatinine clearance from baseline before transplantation   
Platelets  Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count 
Red cells  Decreased hemoglobin or increased red blood cell transfusions Decreased hemoglobin 
CNS Unexplained neurologic dysfunction   
Coombs test Negative direct and indirect  Negative 
Haptoglobin  Decreased Decreased 
Other   No coagulopathy 
CategoryBlood and Marrow Transplant Clinical Trials Network18 International Working Group of the European Group for Blood and Marrow Transplantation58 Probable TMA as defined by validation study by Cho et al53 
Schistocytes ≥ 2 per high-power field in peripheral blood > 4% in peripheral blood ≥ 2 per high-power field in peripheral blood 
LDH Increased above institutional baseline Sudden and persistent increase Increased 
Renal function Doubling of serum creatinine or 50% decrease in creatinine clearance from baseline before transplantation   
Platelets  Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count Thrombocytopenia: < 50 × 109/L or a ≥ 50% decrease in platelet count 
Red cells  Decreased hemoglobin or increased red blood cell transfusions Decreased hemoglobin 
CNS Unexplained neurologic dysfunction   
Coombs test Negative direct and indirect  Negative 
Haptoglobin  Decreased Decreased 
Other   No coagulopathy 

Reprinted by permission from Wolters Kluwer Health.53 

or Create an Account

Close Modal
Close Modal